Show simple item record

dc.contributor.authorKrebs, Matthew G
dc.contributor.authorCarter, Louise
dc.contributor.authorVilla, Shaun
dc.contributor.authorKing, A
dc.contributor.authorMassey, C
dc.contributor.authorLorens, J
dc.contributor.authorDarlington, Emma
dc.contributor.authorFennell, D
dc.date.accessioned2019-02-08T15:20:08Z
dc.date.available2019-02-08T15:20:08Z
dc.date.issued2018en
dc.identifier.citationKrebs M, Carter L, Villa S, King A, Massey C, Lorens J, et al. P2.06-09 MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in pts with malignant mesothelioma. J Thorac Oncol. 2018;13(10):S745.en
dc.identifier.doi10.1016/j.jtho.2018.08.1264en
dc.identifier.urihttp://hdl.handle.net/10541/621519
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2018.08.1264en
dc.titleMiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) incombination with pembrolizumab in pts with malignant mesotheliomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentExperimental Cancer Medicine Team, the Christie NHS Foundation Trust, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record